Creatine monohydrate refills the phosphocreatine energy buffer in muscle and brain. The evidence is strongest for muscle, more than a thousand trials supporting lean-mass and strength gains, including in older adults, while newer RCTs and meta-analyses support cognition under metabolic stress and depression augmentation, and 2-year data shows bone-geometry, not bone-density, benefits. Safety in healthy people is well supported over multi-year use; effects in rested young adults are minimal.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does creatine improve cognition?
Under metabolic stress, yes: a randomized crossover trial showed better memory and processing speed during sleep deprivation, and a 2024 meta-analysis found improved short-term memory and reasoning. In rested, healthy young adults the effect is minimal.11
Does creatine help depression?
Growing evidence says it can augment treatment: an 8-week RCT added it to CBT with a symptom signal, and meta-analyses through 2025 report small-to-moderate effects, strongest as an adjunct in depression, especially in women.2
Is creatine safe long-term?
No kidney harm in healthy people across trials up to five years, and 2-year trials in postmenopausal women matched placebo on adverse events. Caution remains for pre-existing kidney disease.
Form: Creatine monohydrate (CrM) — the only form with a deep evidence base; all "advanced" forms (HCl, buffered, liquid) lack superiority data. Status: The most-studied ergogenic supplement in existence (>1,000 trials), now with rapidly accruing evidence in cognition, depression, menopause, and bone health (2024–2026 wave).
02Overview
In supplementation studies, 3–5 g/day of creatine monohydrate raised muscle phosphocreatine (PCr) 20–40%. Long dismissed as a "bodybuilder supplement," creatine is now one of the few compounds with human RCT evidence spanning muscle performance, brain bioenergetics, mood disorders, and postmenopausal bone geometry — with a 2025 ISSN position stand for older adults and clinical populations (Candow et al., 2025).
Evidence Level: Very strong for muscle/strength; moderate and growing for cognition under stress, depression augmentation, and bone geometry; mixed for resting cognition in healthy young adults.
03Mechanism of Action
1. The Phosphocreatine / Creatine Kinase System
PCr acts as a spatial and temporal energy buffer: - Temporal buffering: The creatine kinase reaction (PCr + ADP + H⁺ ↔ Cr + ATP) regenerates ATP in milliseconds during high-intensity demand - Proton buffering: Consumes H⁺, attenuating acidosis during anaerobic effort - Spatial energy shuttling: The PCr/Cr circuit moves high-energy phosphates from mitochondria (where ATP is made) to sites of use (myofibrils, ion pumps) — functionally analogous to a cellular charge/discharge cycle
2. Brain Bioenergetics
The brain consumes ~20% of resting energy. Creatine kinase isoenzymes in neurons and astrocytes buffer ATP there too, and the brain's creatine pool is smaller and slower to load than muscle (blood–brain barrier limitation; weeks-to-months at low doses). This is why cognitive effects reliably appear under metabolic stress (sleep deprivation, hypoxia, aging, depression) but rarely in rested, healthy, well-slept young adults — the buffer isn't rate-limiting at baseline.
3. Other Mechanisms
- Myonuclei retention / satellite cell activity in older adults (anti-sarcopenic)
- Anti-inflammatory and antioxidant effects (indirect, via improved Ca²⁺ handling)
- Brain pH and NAA ratio changes visible on ³¹P/¹H-MRS spectroscopy — the cleanest in-vivo biomarker of target engagement
04Evidence Taxonomy
A. Muscle Strength, Power, Lean Mass — HUMAN, STRONG
The base layer. Meta-analyses of RCTs consistently show CrM + resistance training increases lean mass (~1–1.5 kg over training alone) and 1RM strength (~8% additive). Effects hold in older adults (60–80+), where the myonuclei-retention mechanism matters most. See the 2025 ISSN position stand (Candow et al., J Int Soc Sports Nutr 22(sup1):2534130) covering older adults and clinical populations.
B. Cognition Under Metabolic Stress — HUMAN, MODERATE–STRONG
- Sleep deprivation: Gordji-Nejad et al. 2024 (Sci Rep 14:4937, open access) — randomized, double-blind, crossover; single high dose 0.35 g/kg (~25 g) during 21 h partial sleep deprivation. ³¹P/¹H-MRS showed increased brain PCr/tCr and reduced ATP/Pi; significant improvements in word memory, processing speed, logic, and numeric tasks vs placebo, plus reduced subjective fatigue. Acute brain bioavailability demonstrated — but note the dose is ~5× maintenance.
- Systematic review, cognition: Xu et al. 2024 (Front Nutr, PMID 39070254; corrigendum PMID 40034739) — improved short-term memory and intelligence/reasoning; other domains inconsistent.
- Pattern: effects concentrate in sleep loss, hypoxia, aging, and mental fatigue; minimal effect in rested healthy adults. Consistent with the buffer-not-limiting model above.
C. Depression and Mental Disorders — HUMAN, GROWING
- RCT, augmentation: Sherpa et al. 2025 (Eur Neuropsychopharmacol 90:28–35) — 8-week double-blind pilot: CrM added to cognitive-behavioral therapy in depression showed better safety/feasibility and symptom signal vs placebo + CBT.
- Meta-analysis: Eckert et al. 2025 (Br J Nutr, published Nov 2025) — systematic review of RCTs on creatine for depressive symptoms.
- Systematic review of mental disorders RCTs (PMC12823350, search through Sep 2025) — pooled evidence across depression, anxiety, schizophrenia; generally small-to-moderate effects, strongest as adjunct in depression (esp. in women, aligned with Lyoo et al. 2012 SSRI augmentation precedent).
- Editorial framing: Fabiano & Stubbs 2025 (Eur Neuropsychopharmacol 95:1) — "muscle and the mind" hypothesis: creatine + exercise for depression.
D. Postmenopausal Women — Muscle and Bone — HUMAN, ACTIVE CONTROVERSY (2026)
This is the current research frontier: - Meta-analysis 2026: Naddafha et al. 2026 (J Int Soc Sports Nutr, PMID 42141930 / PMC13182165) — RCTs in postmenopausal women: benefits for lean mass and strength; bone mineral density effects not significant, but bone geometry signals. - 2-year RCT: Chilibeck et al. 2023 (Med Sci Sports Exerc 55(10):1750–1760) — n=237 postmenopausal women, creatine ~0.1–0.14 g/kg/day + exercise for 2 years: no BMD change at femoral neck/hip/spine, but improved section modulus and buckling ratio (bone strength geometry) at femur. - Earlier signal: Candow et al. 2021 (Osteoporos Int, PMID 33052328) — smaller trials suggesting attenuated bone loss; and a 52-week 1 g/day trial (Lobo et al. 2015) showing femoral bone content ~+1.8% vs +0.4% placebo. - Counterpoint: Osteoporos Int 2025 commentary (10.1007/s00198-025-07713-9) — "insufficient evidence to recommend creatine for osteoporosis." - Bottom line: BMD is not meaningfully improved; bone structural geometry and muscle-related fall-fracture risk factors may be. Doses in positive trials (0.1–0.14 g/kg/day ≈ 7–10 g/day) exceed the standard 3–5 g.
E. Traumatic Brain Injury / Neuroprotection — HUMAN PRELIMINARY + ANIMAL
Pediatric TBI RCTs (Sakellaris et al.) showed improved outcomes; adult data lacking. Animal data robust across TBI, spinal cord injury, Huntington's models. Not clinical practice yet.
F. Vegetarians / Older Adults — Special Populations
Vegetarians and vegans start with lower baseline muscle and brain creatine pools and show the largest response deltas. Older adults need the muscle anti-sarcopenia angle more than the sports angle — see Exercise Science and Longevity.
05Uses
- Timing: Post-workout slightly superior in some trials; consistency matters more than timing.
- No cycling needed; no credible evidence of receptor downregulation — creatine is a substrate, not a signal.
- Response variability: ~20–30% "non-responders" for muscle performance (high baseline pools); vegans respond most.
- Form: Monohydrate only. Creapure® vs generic: purity differences minor; third-party testing (NSF/Informed Sport) matters in tested sport.
06Safety
- Renal: No evidence of kidney harm in healthy individuals across trials up to 5 years (Kreider et al. 2025, J Int Soc Sports Nutr — safety analysis of trials + adverse-event reports). Contraindication caution remains for pre-existing renal disease.
- Postmenopausal women: 2-year trials show adverse events comparable to placebo (Chilibeck 2023).
- Water retention: Early intracellular (+1–2 kg); not fat mass.
- Hair loss: Single small 2009 rugby study (rugby confound); never replicated — treat as myth pending data.
- Long-term: 5+ year pediatric TBI and adult neurology trials without signal emergence.
07Open Questions / Research Gaps
- BMD vs bone geometry — 2-year trials dissociate density from strength geometry; fracture-outcome data absent entirely.
- Brain loading kinetics — how many weeks of what dose maximally loads the human brain (MRS studies ongoing)?
- Depression augmentation — Sherpa 2025 was a pilot; adequately powered Phase-2-style trials still missing.
- Sex differences — women underrepresented historically; menstrual-phase interactions barely studied (one study: CrM increases sleep duration post-resistance-training in naturally menstruating women).
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 3 g/day · Creatine, habitual intake general population (ISSN position stand) PMID 28615996
- Trial up to 30 g/day · Creatine, upper range studied as safe up to 5 years healthy individuals and patient groups (ISSN) PMID 28615996
Further reading: detailed protocols
- ISSN position stand on creatine (open access) jissn.biomedcentral.com
- FoundMyFitness: creatine topic overview foundmyfitness.com
08Connections
09Sources
- Xu C, et al. (2024). "The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis." Front Nutr . PMID 39070254 (corrigendum: PMID 40034739 ).PubMed 39070254 · PubMed 40034739
- PMC12823350PMC12823350
- Naddafha S, et al. (2026). "Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis." J Int Soc Sports Nutr . PMID 42141930 , PMC13182165 .PubMed 42141930 · PMC13182165
- Candow DG, et al. (2021). "Creatine supplementation and changes in bone mineral density in women aged 50–70 years." Osteoporos Int 32:989–998. PMID 33052328 .PubMed 33052328
10Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.